SAN DIEGO, May 17, 2017 - /PRNewswire/ -- ResMed today issued the following statement from David Pendarvis, the company's global general counsel and chief administrative officer:
Experience the interactive Multimedia News Release here: https://www.multivu.com/
"ResMed filed a motion to dismiss the current International Trade
Commission (ITC) complaint so that we can refile and incorporate
additional evidence generated since the original complaint was filed. We
believe this will make our strong case even stronger, and we remain
confident in our position in the ITC. ResMed's innovations have
transformed the treatment of sleep-disordered breathing. We're committed
to protecting our innovation, which is why we've engaged in global
legal proceedings with Fisher & Paykel."
About ResMed
ResMed (NYSE: RMD) changes lives with
award-winning medical devices and cloud-based software applications that
better diagnose, treat and manage sleep apnea, chronic obstructive
pulmonary disease (COPD) and other chronic diseases. ResMed is a global
leader in connected care, with more than 3 million patients remotely
monitored every day. Our 5,000-strong team is committed to creating the
world's best tech-driven medical device company – improving quality of
life, reducing the impact of chronic disease, and saving healthcare
costs in more than 100 countries.
|
For media:
|
For investors:
|
|
Alison Graves
|
Agnes Lee
|
FONTE ResMed
No hay comentarios:
Publicar un comentario